Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

Mark J. Ratain, Tim Eisen, Walter M. Stadler, K. T. Flaherty, Martin Gore

DOI: 10.1200/jco.2005.23.16_suppl.4544

Journal of Clinical Oncology

Data up to Jan 2025

Published2005

Citations100

References0

Fields

Medicine Engineering Internal medicine Gastroenterology Surgery

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

No citing papers found in database

Final findings from a phase II, placebo-controlled, randomized discontinuation trial… (2005) – Journal of Clinical Oncology | Metascience Observatory Explorer